Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erland Erdmann

Showing results (101-110 of 138) with videos related to

Pageof 14
Sort By:
Cardiovascular Research|December 17, 2008
Differential effects of red and white wines on inhibition of the platelet-derived growth factor receptor: impact of the mash fermentationJan Sparwel, Marius Vantler, Evren Caglayan, et al.
Plos One|July 14, 2010
Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillationAmir M Nia, Evren Caglayan, Natig Gassanov, et al.
Plos One|March 23, 2012
Clinical impact of atrial fibrillation in patients with pulmonary hypertensionDennis Rottlaender, Lukas J Motloch, Daniela Schmidt, et al.
Journal of Cardiac Failure|October 18, 2008
Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trialBarry F Uretsky, Kristian Thygesen, Jean-Claude Daubert, et al.
European Heart Journal|April 14, 2005
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER surveyMichel Komajda, Pablo Lapuerta, Nancy Hermans, et al.
Circulation|May 11, 2013
Response to letter regarding article, "Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized Pilot RenPro-Trial (Renal Protection Trial)"Fikret Er, Amir M Nia, Henning Dopp, et al.
American Heart Journal|June 22, 2015
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetesErland Erdmann, Robert Califf, Hertzel C Gerstein, et al.
European Journal of Heart Failure|June 9, 2004
Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-IIIRonnie Willenheimer, Erland Erdmann, Ferenc Follath, et al.
Diabetes Care|August 2, 2007
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)Erland Erdmann, Bernard Charbonnel, Robert G Wilcox, et al.
Circulation|June 28, 2012
Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial)Fikret Er, Amir M Nia, Henning Dopp, et al.
Pageof 14

Showing results (101-110 of 138) with videos related to

Sort By:
Pageof 14
Cardiovascular Research|December 17, 2008
Differential effects of red and white wines on inhibition of the platelet-derived growth factor receptor: impact of the mash fermentationJan Sparwel, Marius Vantler, Evren Caglayan, et al.
Plos One|July 14, 2010
Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillationAmir M Nia, Evren Caglayan, Natig Gassanov, et al.
Plos One|March 23, 2012
Clinical impact of atrial fibrillation in patients with pulmonary hypertensionDennis Rottlaender, Lukas J Motloch, Daniela Schmidt, et al.
Journal of Cardiac Failure|October 18, 2008
Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trialBarry F Uretsky, Kristian Thygesen, Jean-Claude Daubert, et al.
European Heart Journal|April 14, 2005
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER surveyMichel Komajda, Pablo Lapuerta, Nancy Hermans, et al.
Circulation|May 11, 2013
Response to letter regarding article, "Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized Pilot RenPro-Trial (Renal Protection Trial)"Fikret Er, Amir M Nia, Henning Dopp, et al.
American Heart Journal|June 22, 2015
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetesErland Erdmann, Robert Califf, Hertzel C Gerstein, et al.
European Journal of Heart Failure|June 9, 2004
Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-IIIRonnie Willenheimer, Erland Erdmann, Ferenc Follath, et al.
Diabetes Care|August 2, 2007
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)Erland Erdmann, Bernard Charbonnel, Robert G Wilcox, et al.
Circulation|June 28, 2012
Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial)Fikret Er, Amir M Nia, Henning Dopp, et al.
Pageof 14